A Phase 2 interventional study of Placebo and Ketamine in Major Depressive Disorder, sponsored by Janssen Research & Development, LLC. Completed at 13 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing ketamine in Depressive Disorder, Major — 21 open to participants now, 26 under way, 5 of them phase 3. Ketamine · Depressive Disorder, Major.
Among the 89 studies testing ketamine in Depressive Disorder, Major, this one is the 26th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 2, and was the 12th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →21 of the 89 studies testing ketamine in Depressive Disorder, Major are open now, in 9 countries. Recruiting first, the newest first:
Joshua Rosenblat · Sites in Canada
Ages 18–70
University of Pennsylvania · Sites in United States
Ages 25–65
Università Vita-Salute San Raffaele · Sites in Italy
Ages 18–70
The Royal's Institute of Mental Health Research · Sites in Canada
Ages 18–65
Mayo Clinic · Sites in United States
Ages 18–65
By country, each count listing its studies:
Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 32 · Phase 3 13 · Phase 4 16
First in 2004; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is below the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 38 across the 89 interventional studies. Of the 48 that completed or were terminated, 29 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 89 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
59 studies in Depressive Disorder, Major by Johnson & Johnson: 5 open now, 5 under way, 5 of them phase 3. Of 53 finished, 26 (49%) have results posted.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 39th largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2012, is one of 17 in phase 2, and was the 9th registered.
Johnson & Johnson’s Depressive Disorder, Major studies by the year they started, since 2002.
11 of the studies testing ketamine in Depressive Disorder, Major that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06891300Phase 3The Royal's Institute of Mental Health ResearchUnderstanding and Treating Suicidal Ideation With Ketamine | 2027-03 |
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT06228391Minneapolis Veterans Affairs Medical CenterKetamine Treatment for PTSD and MDD in TBI | 2026-12 |
| NCT06788249University of PennsylvaniaPilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine | 2026-12-15 |
| NCT06480201Texas A&M UniversityGamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 89 studies testing ketamine in Depressive Disorder, Major, from their registry updates:
Among Johnson & Johnson’s 59 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to explore the optimal dose frequency of ketamine in patients with treatment-resistant depression (TRD).
This is a double-blind (patients and study personnel do not know the identity of the administered treatments), randomized (the drug is assigned by chance), placebo-controlled (placebo is a substance that appears identical to the treatment and has no active ingredients), parallel arm study (each group of patients will be treated at the same time). The study will consist of a screening phase of up to 4 weeks, a 4-week double-blind treatment phase (Day 1 to Day 29), and a 3-week post treatment (follow up) phase. In the double-blind phase, patients will receive over 4 weeks either intravenous (IV) infusions of placebo (2 or 3 times weekly) or IV infusions of ketamine (2 or 3 times weekly). The total study duration for each patient will be a maximum of 13 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Ketamine
Drug: Ketamine
Drug: Placebo
Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 15
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
Time frame: Baseline (Day 1) and Day 15
Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 29
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
Time frame: Baseline (Day 1) and Day 29
Number of Responders Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Participants with a reduction in the MADRS total score of greater than or equal to (\>=) 50 percent from baseline were defined as responders. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
Time frame: Day 15 and Day 29
Number of Remitters Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Participants who had a MADRS total score of less than or equal to (\<=) 10 were considered remitters. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
Time frame: Day 15 and Day 29
Number of Sustained Responders Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Sustained response on Day 15 was defined as achieving an onset of antidepressant response within the first week that is maintained to the end of study Day 15. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
Time frame: Day 15
Change in Clinical Global Impression-Severity (CGI-S) Score From Baseline to Endpoint (Day 29)
The CGI-S was used to rate the severity of the participants illness at the time of assessment, relative to the clinician's past experience with participants who had the same diagnosis and improvement with treatment. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to: 0= not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants.
Time frame: Baseline (Day 1) and Endpoint (Day 29)
Clinical Global Impression of Improvement (CGI-I) Score at Endpoint of Double Blind Phase
The CGI-I is a 7-point scale that was used to assess how much the participants illness was improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 0= not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.
Time frame: Endpoint (Day 29)
Change in Patient Global Impression-Severity (PGI-S) Score From Baseline to Endpoint (Day 29)
The PGI-S is an 11-point (0 to 10) scale that required the participant to rate the severity of their illness at the time of assessment, relative to the participants past experience. Considering their total experience, the participant was to assess the severity of their depression illness at the time of rating as none, mild, moderate or severe. The scale is rated as, 0=very well and 10=very poor.
Time frame: Baseline (Day 1) and Endpoint (Day 29)
Patient Global Impression-Change (PGI-C) Score at Endpoint of Double Blind Phase
The PGI-C is a 7-point scale that required the subject to assess how much their illness had improved or worsened relative to a baseline state at the beginning of the intervention. The response options were: very much improved; much improved; improved (just enough to make a difference); no change; worse (just enough to make a difference); much worse; or very much worse. The scale is rated as, 1=very much improved and 7=very much worse.
Time frame: Endpoint (Day 29)
Maximum Observed Plasma Concentration (Cmax) of Ketamine
The Cmax is the maximum observed plasma concentration of drug.
Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ketamine
The Tmax is defined as actual sampling time to reach maximum observed drug concentration.
Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC[0-last])
The AUC(0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.
Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity])
The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC (last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
Total Systemic Clearance (CL) of Ketamine
The CL is a quantitative measure of the rate at which a drug substance is removed from the body.
Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
Volume of Distribution at Steady-State (Vss) of Ketamine
The Vss is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of ketamine at steady state.
Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
Elimination Half-Life (t1/2)
The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
Time frame: Pre-infusion, 20, 40 (End of the Infusion), 45, 50, 60, 90, 120, 180, 240 and 360 minutes post-infusion on Day 1 and Day 15
| Milestone | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|---|---|
| Started | 17 | 18 | 16 | 17 |
| Treated | 16 | 18 | 16 | 17 |
| Completed | 1 | 12 | 1 | 11 |
| Not completed | 16 | 6 | 15 | 6 |
| Withdrew: Adverse event | 1 | 2 | 0 | 1 |
| Withdrew: Lack of efficacy | 11 | 1 | 15 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 0 | 3 |
| Withdrew: Randomized but not treated | 1 | 0 | 0 | 0 |
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
| Units on a scale | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|---|---|
| Baseline (n=16,18,16,17) | 35.6 ± 3.79 | 33.3 ± 4.91 | 36.8 ± 5.83 | 35.4 ± 5.28 |
| Change at Day 15 (n=13,16,16,13) | -5.7 ± 10.23 | -18.4 ± 12.01 | -3.1 ± 5.67 | -17.7 ± 7.27 |
The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
| Units on a scale | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|---|---|
| Baseline (n=16,18,16,17) | 35.6 ± 3.79 | 33.3 ± 4.91 | 36.8 ± 5.83 | 35.4 ± 5.28 |
| Change at Day 29 (n=2,13,1,13) | -23.5 ± 10.61 | -27.1 ± 6.60 | -1 ± NA | -22.9 ± 10.61 |
Participants with a reduction in the MADRS total score of greater than or equal to (\>=) 50 percent from baseline were defined as responders. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
| Participants | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|---|---|
| Day 15 (n=13,16,16,13) | 2 ± 3.79 | 11 ± 4.91 | 1 ± 5.83 | 7 ± 5.28 |
| Day 29 (n=2,13,1,13) | 1 ± 10.61 | 13 ± 6.60 | 0 ± NA | 9 ± 10.61 |
Participants who had a MADRS total score of less than or equal to (\<=) 10 were considered remitters. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
| Participants | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|---|---|
| Day 15 (n=13,16,16,13) | 1 ± 3.79 | 6 ± 4.91 | 0 ± 5.83 | 3 ± 5.28 |
| Day 29 (n=2,13,1,13) | 1 ± 10.61 | 12 ± 6.60 | 0 ± NA | 5 ± 10.61 |
Sustained response on Day 15 was defined as achieving an onset of antidepressant response within the first week that is maintained to the end of study Day 15. The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60. Higher scores represent a more severe condition.
| Participants | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|---|---|
| Number of Sustained Responders Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | 1 ± 3.79 | 7 ± 4.91 | 0 ± 5.83 | 4 ± 5.28 |
The CGI-S was used to rate the severity of the participants illness at the time of assessment, relative to the clinician's past experience with participants who had the same diagnosis and improvement with treatment. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to: 0= not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants.
| Units on a scale | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|---|---|
| Baseline (n=15,18,16,17) | 5.0 ± 3.79 | 5.0 ± 4.91 | 5.0 ± 5.83 | 5.0 ± 5.28 |
| Change at Endpoint (n=15,18,16,17) | 0.0 ± 10.61 | -2.0 ± 6.60 | 0.0 ± NA | -2.0 ± 10.61 |
The CGI-I is a 7-point scale that was used to assess how much the participants illness was improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 0= not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.
| Units on a scale | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|---|---|
| Clinical Global Impression of Improvement (CGI-I) Score at Endpoint of Double Blind Phase | 4.0 ± 3.79 | 2.0 ± 4.91 | 4.0 ± 5.83 | 2.0 ± 5.28 |
The PGI-S is an 11-point (0 to 10) scale that required the participant to rate the severity of their illness at the time of assessment, relative to the participants past experience. Considering their total experience, the participant was to assess the severity of their depression illness at the time of rating as none, mild, moderate or severe. The scale is rated as, 0=very well and 10=very poor.
| Units on a scale | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|---|---|
| Baseline (n=15,18,16,17) | 8.0 ± 3.79 | 7.5 ± 4.91 | 8.0 ± 5.83 | 7.0 ± 5.28 |
| Change at Endpoint (n=15,18,16,17) | 0.0 ± 10.61 | -4.0 ± 6.60 | -1.0 ± NA | -3.0 ± 10.61 |
The PGI-C is a 7-point scale that required the subject to assess how much their illness had improved or worsened relative to a baseline state at the beginning of the intervention. The response options were: very much improved; much improved; improved (just enough to make a difference); no change; worse (just enough to make a difference); much worse; or very much worse. The scale is rated as, 1=very much improved and 7=very much worse.
| Units on a scale | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|---|---|
| Patient Global Impression-Change (PGI-C) Score at Endpoint of Double Blind Phase | 4.0 ± 3.79 | 2.0 ± 4.91 | 4.0 ± 5.83 | 3.0 ± 5.28 |
The Cmax is the maximum observed plasma concentration of drug.
| nanogram per milliliter (ng/ml) | Ketamine: 2 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|
| Day 1 (n=16,16) | 207 ± 83.0 | 168 ± 34.4 |
| Day 15 (n=14,15) | 219 ± 69.4 | 189 ± 74.4 |
The Tmax is defined as actual sampling time to reach maximum observed drug concentration.
| Hour | Ketamine: 2 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|
| Day 1 (n=16,16) | 0.67 ± 83.0 | 0.66 ± 34.4 |
| Day 15 (n=14,15) | 0.67 ± 69.4 | 0.67 ± 74.4 |
The AUC(0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.
| hour*nanogram per milliliter | Ketamine: 2 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|
| Day 1 (n=16,15) | 312 ± 67.9 | 295 ± 42.8 |
| Day 15 (n=14,14) | 342 ± 66.7 | 293 ± 65.6 |
The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC (last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
| hour*nanogram per milliliter | Ketamine: 2 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|
| Day 1 (n=13,13) | 369 ± 79.9 | 344 ± 47.3 |
| Day 15 (n=9,8) | 416 ± 68.9 | 340 ± 94.0 |
The CL is a quantitative measure of the rate at which a drug substance is removed from the body.
| liter per hour | Ketamine: 2 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|
| Day 1 (n=13,13) | 113 ± 35.1 | 108 ± 21.4 |
| Day 15 (n=9,8) | 93.9 ± 15.6 | 117 ± 22.3 |
The Vss is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of ketamine at steady state.
| liter | Ketamine: 2 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|
| Day 1 (n=13,13) | 275 ± 114 | 276 ± 77.2 |
| Day 15 (n=9,8) | 239 ± 61.2 | 290 ± 64.9 |
The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
| hour | Ketamine: 2 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|
| Day 1 (n=13,13) | 2.18 ± 0.43 | 2.18 ± 0.40 |
| Day 15 (n=9,8) | 2.39 ± 0.36 | 2.21 ± 0.36 |
Collected over Screening up to Follow up (3 Weeks After Last Dose of Study Drug Administration). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo: 2 Times Per Week | — | 0/16 (0%) | 9/16 (56.3%) |
| Ketamine: 2 Times Per Week | — | 2/18 (11.1%) | 15/18 (83.3%) |
| Placebo: 3 Times Per Week | — | 0/16 (0%) | 8/16 (50%) |
| Ketamine: 3 Times Per Week | — | 0/17 (0%) | 13/17 (76.5%) |
| Event | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|---|---|
| AnxietyPsychiatric disorders | 0/16 | 1/18 | 0/16 | 0/17 |
| Suicide AttemptPsychiatric disorders | 0/16 | 1/18 | 0/16 | 0/17 |
| Event | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week |
|---|---|---|---|---|
| HeadacheNervous system disorders | 5/16 | 4/18 | 1/16 | 7/17 |
| DissociationPsychiatric disorders | 0/16 | 5/18 | 0/16 | 1/17 |
| NauseaGastrointestinal disorders | 1/16 | 3/18 | 2/16 | 4/17 |
| DizzinessNervous system disorders | 1/16 | 4/18 | 0/16 | 2/17 |
| AnxietyPsychiatric disorders | 0/16 | 4/18 | 0/16 | 1/17 |
| HypoaesthesiaNervous system disorders | 0/16 | 2/18 | 0/16 | 3/17 |
| FatigueGeneral disorders | 0/16 | 0/18 | 0/16 | 2/17 |
| ParaesthesiaNervous system disorders | 0/16 | 1/18 | 0/16 | 2/17 |
| Vision BlurredEye disorders | 0/16 | 2/18 | 0/16 | 0/17 |
| Blood Pressure IncreasedInvestigations | 0/16 | 2/18 | 0/16 | 0/17 |
The Intent-To-Treat (ITT) analysis set is defined as participants who were randomized and received at least 1 dose of the study drug.
| Age, Continuous(years) | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week | Total |
|---|---|---|---|---|---|
| Mean | 40.3 ± 11.79 | 45.7 ± 9.58 | 46.1 ± 10.51 | 43.3 ± 11.99 | 43.9 ± 10.9 |
| Sex: Female, Male(Participants) | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week | Total |
|---|---|---|---|---|---|
| Female | 12 | 12 | 9 | 12 | 45 |
| Male | 4 | 6 | 7 | 5 | 22 |
| Region of Enrollment(participants) | Placebo: 2 Times Per Week | Ketamine: 2 Times Per Week | Placebo: 3 Times Per Week | Ketamine: 3 Times Per Week | Total |
|---|---|---|---|---|---|
| USA | 16 | 18 | 16 | 17 | 67 |
Ran from Aug 2012 to primary completion in Sep 2013, 13 months.
Results were first posted in Aug 2016, 2 years 10 months after primary completion. A results delay was requested in Jun 2014.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 13 months is below that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ketamine
Janssen Research & Development, LLC →